This study assessed the safety and efficacy of a commercial low-citrate concentration-based pre-filter replacement fluid during continuous veno-venous haemofiltration (CVVH) in patients with frequent filter clotting and high risk of bleeding. We used a commercial low-citrate fluid as pre-dilution replacement fluid during CVVH (citrate: 11 mmol/l (33 meq/l), sodium: 140 mmol/l, chloride: 108 mmol/l and potassium: 1 mmol/l). A calcium and magnesium infusion was delivered separately by central line for the maintenance of serum ionized calcium (Ca i ) and total magnesium (Mg). In this prospective observational study, 30 patients, 124 filters and 1,515 treatment-hours were observed. Median filter life of citrate CVVH was 9.5 hours. Filter life in the 48 hours prior to citrate CVVH was also observed. In the patients on prior non-anticoagulant CVVH (n=14) filter life increased significantly with citrate (9.5 hours vs 5 hours; P<0.0001). In patients on prior heparin CVVH (n=15), filter life was similar with citrate (10 hours vs 8 hours; P=0.68). However, in patients with prior early/frequent filter clotting despite heparin (n=11) filter life increased significantly (10 hours vs 7 hours; P=0.038). Of 411 serum Ca i measurements, none showed a Ca i <0.85 mmol/l and, of 84 observations, none showed a serum Mg<0.6mmol/l. One patient with sepsis and shock needed to cease citrate CVVH because of progressive ionized hypocalcaemia and increasing anion gap. No other adverse effects were observed. In selected patients, CVVH with a commercial low-citrate concentration solution as pre-filter replacement fluid and a simultaneous calcium and magnesium infusion protocol appears generally safe. Filter life was acceptable and superior to that achieved with previous treatment.
Continuous renal replacement therapy (CRRT) is increasingly being used as renal replacement therapy for critically ill patients with acute renal failure [1] [2] [3] . One of the main disadvantages of CRRT is its requirement for continued anticoagulation in order to prevent clotting of the extra-corporeal circuit. Heparin anticoagulation is a common method of anticoagulation, although side-effects such as bleeding and heparin-induced thrombocytopenia have been reported 4, 5 . Alternative methods of anticoagulation have been reported. They include regional heparinization with post-filter protamine reversal 6, 7 , low molecular-weight heparin [8] [9] [10] , nafamostat mesylate [11] [12] [13] , prostacyclin 14, 15 , saline flushes 4, 16, 17 or CRRT without anticoagulation [17] [18] [19] . However, because of cost, complexity and limited success, these methods have not achieved widespread use and heparin is probably still the main choice for anticoagulation worldwide, including Australia.
Regional citrate anticoagulation (RCA) for CRRT is an alternative approach that can avoid the side-effects of heparin 20, 21 . RCA has been reported to carry a low risk of bleeding and filter clotting [20] [21] [22] [23] . Recently a number of protocols for citrate CRRT have been studied [20] [21] [22] [23] [24] [25] [26] . Most of them have used diffusion-based CRRT (continuous veno-venous haemodialysis (CVVHD) or haemodiafiltration (CVVHDF)), custom-made dialysate solutions 20, [22] [23] [24] [25] [26] , concentrated 4% trisodium citrate infusion 20, 22, 23 or anticoagulant citrate dextrose-A solutions 27 . Almost all of these protocols have achieved some success in the institution where they were applied. However, RCA has not yet achieved widespread adoption worldwide and not at all in Australia because of a) the lack of uniformity in therapeutic approaches reported in the literature, b) the cost and logistics of obtaining custom-made solutions, c) the limited information available on RCA for non-diffusive CRRT, d) the lack of approval for intravenous administration of anticoagulant citrate dextrose-A solutions in some countries, e) the perceived concern about the complexity of monitoring calcium levels, f) concern about possible errors when three solutions are being administered (calcium solution, citrate solution, custom-made low sodium and no calcium replacement/dialysate fluids) simultaneously and g) the common development of metabolic alkalosis caused by exogenous sodium citrate administration.
We sought to overcome some of these disadvantages by developing a citrate-containing replacement fluid for CVVH-based on protocols proposed by Palsson and colleagues 21 and Dorval and co-workers 26 , with modifications toward a lower citrate dose to maximize safety and apply a simple calcium and magnesium infusion protocol. We now present our initial experience.
MATERIALS AND METHODS
This study was conducted from July 2003 to July 2004 in the intensive care units (ICUs) of tertiary public and affiliated private hospitals (four hospitals). The prospective collection of data was classified as a quality improvement audit with waiving of the need for informed consent by the Ethics Committee.
CVVH procedure
CVVH was performed with BMMO-1 Blood Module (Gambro, Lund, Sweden) with volumetric IV pump for replacement fluid and ultrafiltration control, Hygieia (Kimal PLC, Uxbridge, Middlesex, U.K.) or Aquarius (Edwards Life Sciences, Sydney, N.S.W., Australia) machines. Veno-venous access was secured by inserting a 13.5-Fr double-lumen catheter (Niagara, Vascath, Ont, Canada) into a central vein (commonly femoral veins). Either AN69 (Hospal, Lyon, France) or APS650 (Asahi Medical, Tokyo, Japan) hollow-fibre haemofilters were used. Blood flow rate was kept at 166 ml/min in the BMMO-1 machine (Gambro, Lund, Sweden) and 200 ml/min in other machines. Filters were changed for suspected clotting if trans-membrane pressure (TMP) was high (approximately >200 mmHg) and/or if the blood flow was halted by visible clotting and/or ultrafiltrate pressure alarm persistently showed "low flow". Serum electrolytes and arterial blood gases (ABGs) were monitored every six hours or more frequently if needed.
Commercial lactate-buffered replacement fluid containing 45 mmol/l of lactate, 140 mmol/l of sodium, 101 mmol/l of chloride, 1 mmol/l of potassium, 1.63 mmol/l of calcium and 0.75 mmol/l of magnesium (Haemofiltration Solutions, Baxter, Sydney, Australia) was infused pre-filter at the rate of 2000 ml/h. When lactic acidaemia (lactate >5 mmol/l) occurred, the replacement fluid was switched to lactate-free bicarbonate-buffered replacement fluid containing lactate 3 mmol/l, bicarbonate 32 mmol/l, sodium 140 mmol/l, chloride 109 mmol/l, potassium 1 mmol/l, calcium 1.75 mmol/l and magnesium 0. 5 mmol/l (Gambro-Hospal, Sydney, Australia).
Protocol for CVVH with heparin
Anticoagulation was typically conducted with 5 IU/kg/h of heparin. Heparin 10 IU/kg/h was infused if patients had at least two of the following: an international normalized ratio (INR) <1.5, APTT <40s and platelet counts >150210 3 /µl.
Protocol for CVVH with heparin or nonanticoagulation
Risk of bleeding and/or contraindication of heparin was defined as (1) patients had at least two of the following: INR>2.5, APTT>60s and platelet count <60210 3 /µl, (2) had had recent major surgery in the preceding 24-48 hours or (3) had known sensitivity to heparin. Clinician judgement was applied to other situations. In patients defined as above, anticoagulantfree CVVH was applied.
Protocol for CVVH with citrate
Patients who had a high risk of bleeding or contraindications to heparin or very short filter life with the above approach to anticoagulation were eligible to receive citrate-CVVH. Exclusion criteria were acute or chronic liver failure or suspected ischaemic hepatitis. Commercial citrate-buffered replacement fluid (Baxter, Sydney, Australia; marketed by Edwards Lifesciences, Sydney, Australia) was infused pre-filter at the rate of 2000 ml/h. This replacement fluid was in 5-litre bags and contained 11 mmol/l (33Eq/l of buffer equivalent) of citrate, 140 mmol/l of sodium, 108 mmol/l of chloride and 1 mmol/l of potassium. Potassium was further adjusted, once hyperkalaemia had been corrected, by the addition of 15 mmol of potassium chloride to a 5-litre fluid bag (i.e. 3 mmol/l). Total calcium and magnesium were measured daily.
A solution containing calcium and magnesium in saline (70 ml of 0.9% saline, with 100 ml (70 mmol) of CaCl 2 and 35 ml (35 mmol) of MgCl 2 ) was administered via a central line according to protocol (Figure 1 ).
Filter patency
Time to circuit failure, the primary outcome variable, was measured from the time of commencement to the time of elective discontinuation (for example, surgery) or circuit clotting. Prior filter life, within 48 hours of low-citrate CVVH, was also observed.
Statistical analysis
Continuous data are presented as medians with interquartile range (25th, 75th percentile) and dichotomous data are presented as percentages, unless otherwise indicated. A P value less than 0.05 was considered to indicate statistical significance. Differences between two pair groups were assessed using the Wilcoxon signed rank test. Time to filter failure was compared using the Log rank test and presented with Kaplan-Meier survival curves.
RESULTS

Clinical features
The clinical and demographic features of the 30 patients who received citrate CVVH are shown in Table 1 . Twenty patients were admitted to one hospital and 8 patients were admitted to the other hospitals. Fifty per cent of these patients were septic and 43% were postoperative patients. Patient anticoagulation approach and reason for citrate CVVH are shown in Table 2 . Prior to citrate CVVH, 12 patients received CVVH without anticoagulation and 13 received lowdose heparin CVVH. Three patients used citrate CVVH from the beginning. Two patients had both methods intermittently. One experienced early filter clotting with both regimens, another had ongoing concerns about bleeding during heparin CVVH and early filter clotting with non-anticoagulant CVVH. In total we observed 15 patients who received heparin CVVH prior to citrate CVVH (11 patients with early/ frequent filter clotting and 4 patients with bleeding), 14 patients who received non-anticoagulant CVVH prior to citrate CVVH (all with early/frequent filter clotting), and 3 patients who started treatment with citrate CVVH.
Filter Function
Filter life was available for 124 filters in 30 patients ( Table 3 ). The total duration of citrate CVVH was 1,515h. Overall median filter life was 9.5 hours ( Table 3 ). In patients on anticoagulant-free CVVH, filter life was significantly longer after changing to citrate CVVH (9.5 vs 5 hours; P<0.0001) ( Figure  2 ). In patients on heparin CVVH, however, filter life did not change (10 vs 8 hours; P=0.68) (Figure 3 ).
Finally, in patients who required citrate CVVH due to early/frequent filter clotting despite heparin, filter life increased with citrate CVVH (10 vs 7 hours; P=0.038) (Figure 4 ).
Systemic ionized calcium and magnesium concentration during citrate CVVH
We collected details of systemic ionized calcium (Ca i ) and total magnesium (Mg) data during citrate-CVVH at the Austin Hospital's ICU in 22 patients (73%) for 1,123 treatment-hours. Median Ca i was 1.19 (1.1, 1.26) mmol/l. Mild hypocalcaemia (0.85 and 0.95 mmol/l) occurred in four patients and seven measurements. The Ca i level was never less than 0.85 mmol/l. However, there was an episode of a Ca i of 0.55 mmol/l during treatment at another hospital.
Median Mg level was 1.13 (0.96, 1.30) mmol/l. Mild hypomagnesaemia (0.6 and 0.7 mmol/l) occurred in two patients and two measurements. No Mg level <0.6 mmol/l was recorded.
T. Naka, M. Egi ET al 
Post-filter ionized calcium and anion gap
We collected details of post-filter ionized calcium (Ca i ) and anion gap data during citrate-CVVH at the Austin Hospital's ICU in 16 patients (53%) for 42 treatments (filters). Median post-filter Cai was 0.53 (0.46, 0.58) mmol/l. Post-filter anion gap was significantly higher than pre-filter anion gap (18.2 (16.2, 22.2) mEq/l vs 11.8 (9.2, 14.4) mEq/l; P<0.0001). The average difference of anion gap between preand post-filter was 6.0 (4.3, 8.4) mEq/l.
Complications
No patient developed bleeding during citrate CVVH, despite the high-risk populations. One patient who had sepsis with shock suffered from CiTraTE CVVH Filter life and number of treatment of each group are reported as median filter life (IQR) and no. CVVH: continuous veno-venous haemofiltration.
FigurE 2:
Kaplan-Meier estimation of filter patency probability for CVVH with regional citrate anticoagulation (solid line) and, prior CVVH without anticoagulation (broken line). CVVH: continuous veno-venous haemofiltration. probable citrate toxicity shown by progressive lowserum-ionized calcium, increased total calcium and decreasing base excess. This patient had slightly abnormal liver function tests before citrate CVVH (ALP; 292 IU/l, GGT; 146 IU/l, AST 93 IU/l and total bilirubin; 36 µmol/l). Before starting citrate CVVH, systemic Cai (1.03 mmol/l) and anion gap (12.0 mmol/l) were normal and base excess was 6.0 mEq/l. Six hours after commencement of citrate CVVH, systemic Cai and base excess decreased to 0.55 mmol/l and -2.1 mmol/l, and anion gap increased to 16.5 mmol/l. Treatment was stopped with full biochemical recovery.
DISCUSSION
We conducted a prospective assessment of the introduction of a new commercial citrate replacement fluid aimed at achieving regional anticoagulation during CVVH. We found that, in selected patients at high risk of bleeding or with frequent filter clotting, CVVH with a commercial solution containing a low-citrate concentration and administered prefilter achieved better filter life than CVVH without anticoagulation and low-dose heparin CVVH with early/frequent filter clotting.
This increase in filter life was achieved with only a single episode of severe ionized hypocalcaemia, with no bleeding and with a simple protocol that only required the additional administration of a calcium and magnesium solution. This observation has important implications for intensive care clinicians and requires some discussion.
In 1990, Mehta and his colleagues studied RCA with 4% trisodium citrate during continuous arteriovenous haemodiafiltration (CAVHD) in 11 patients with ARF. Their median filter life for RCA tended to be superior to heparin CAVHD (P=0.186). Later Kutsogiannis and his colleagues reported their experience of RCA with 4% trisodium citrate during continuous haemodiafiltration (CVVHDF). They reported a median filter survival time of 3.4 days (82 h). Palsson and his colleagues examined RCA with citrate based replacement fluid during CVVH in 17 patients with contraindications to heparin anticoagulation. The fluid contained citrate at 13.3mmol/l, which was infused pre-filter leading to a mean filter life span of 29.5±17.9 hours. Recently, Thoenen and his colleagues also studied RCA with citrate-based fluid during CVVH in 31 cardiac surgery patients. The replacement fluid administered prefilter contained citrate at 18 mmol/l 24 with satisfactory results. Compared to these reports, our replacement fluid had a relatively low dose of citrate (11 mmol/l) and relatively short filter life. However, our RCA achieved a filter life similar to that of heparin CVVH and longer than anticoagulation-free CVVH and heparin CVVH with early/frequent filter clotting.
Our study has several strengths. Data were collected prospectively as part of a planned audit of efficacy and safety for a new protocol. The regimen was conducted in four hospitals and is therefore multicentre in nature. However, 73% (22 patients) of our patients came from one centre, thus attenuating the advantages of multi-centre assessment. Furthermore, our study was neither randomized nor crossover in design, making comparisons potentially biased and inaccurate. Nonetheless, our observations suggest at least a high likelihood of equivalence in terms of efficacy. They also suggest that citrate CVVH would be a viable choice in patients with recurrent filter clotting or with absolute contraindications to heparin. Our median filter life was short. However, the current study was designed to evaluate citrate CVVH in a selected population where filter life was very short and anticoagulation with heparin was considered risky. Furthermore, as this was our first experience with citrate anticoagulation, for reasons of safety, we used a low concentration of citrate in the replacement fluid.
Our study also has limitations. For example, this approach to RCA would have resulted in a citrate concentration in the extra-corporeal circuit of 1.83 or 1.57 mmol/l at blood flows of 166 or 200 ml/min respectively. This is a low concentration. When measured, the median post-filter ionized calcium concentration was 0.53 mmol/l, which indicates only limited chelation of calcium. These observations suggest the need to optimize RCA dose. In response to this initial experience, we have started to evaluate a replacement fluid containing more citrate (14 mmol/l; 42 meq/l) to determine whether it can achieve better filter life and maintain safety.
In terms of safety it is important to note that one patient developed signs of likely citrate accumulation in the form of progressive low systemic serum Cai, increased total serum calcium and decreasing base excess. This resolved with cessation of citrate administration and highlights the need to consider the adequacy of liver function when prescribing citrate-CVVH.
An increasing anion gap may indicate an accumulation of citrate (an unmeasured acid or trivalent anion) in the systemic circulation. Such accumulation induces metabolic acidosis by affecting the strong ion difference and, in severe cases, could induce acidaemia. Consistent with this view, such a change in anion gap was also observed in the post-filter anion gap value. Increasing anion gap may be another sign of citrate accumulation in systemic blood.
Finally, Cai and Mg control was satisfactory throughout the study with only a few cases of mild hypocalcaemia and hypomagnesaemia.
Recently, three types of citrate solutions (trisodium citrate 20, 22, 23 , ACD-A27 and citrate containing replacement fluid 21, [24] [25] [26] were reported for citrate CRRT. Trisodium citrate (140 mmol/l (420 meq/l) of citrate and 420 meq/l of sodium) and ACD-A (113 mmol/l (229 meq/l) of citrate and 224 mmol/l of sodium) are hypertonic solutions used for CVVHD 20, 23 or CVVHDF 22, 27 but not for CVVH. These solutions require custom-made dialysate and replacement fluids with reduced sodium and bicarbonate concentration to counterbalance the effect of sodium citrate. This approach increases the risk of treatment errors and pharmacy costs and decreases simplicity. Our ICU nurses found our anticoagulation regimen simple and easy to execute because replacement fluid administration is exactly the same as for standard lactate or bicarbonate CVVH and the only additional element is the infusion of calcium and magnesium. This infusion typically required infrequent adjustments.
We are not aware any other study, which used a commercial solution and fixed blood flow and citrate infusion rates for CVVH. Other studies monitored citrate anticoagulation with post-filter ACT 20, 26 or ionized calcium concentration [21] [22] [23] [24] [25] [26] and adjusted citrate infusion to achieve adequate filter life 20, 22 . However, these methods need frequent measurements and adjustments of citrate and calcium infusion rate and remove simplicity.
In conclusion, we have developed an approach to RCA-CVVH using a commercial citrate-containing fluid as replacement fluid and a simple calcium and magnesium infusion protocol. This approach created protocol uniformity, avoided the costs and logistic burden of obtaining custom-made solutions, increased our knowledge about RCA for non diffusive CRRT, avoided the problem associated with the lack of approval for intravenous administration of anticoagulant citrate dextrose-A solutions in Australia, removed the perceived concern about the complexity of monitoring calcium levels and decreased the risk of error associated with the administration of multiple solutions. Filter life was acceptable and perhaps improved. Having established this inception protocol and successfully executed it with a solution containing a low-citrate concentration, we have now moved to the use of a new citrate replacement fluid containing 14mmol/l of citrate to increase filter life, while maintaining simplicity and safety during CVVH.
